Acucela Data in Dry AMD to be Highlighted at the 8th International Symposium on Ocular Pharmacology and Therapeutics (Business Wire via Yahoo! Finance)
November 23rd, 2009
BOTHELL, Wash.—-Acucela, a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, announced today that data for the company’s novel visual cycle modulator, ACU-4429, a potential oral treatment for dry age-related macular degeneration , will be featured at the 8th International Symposium on Ocular Pharmacology and Therapeutics being held in Rome …
Original post by macular degeneration – Google News
(click on the author/publication link above to see full post)